Stock Track | Moderna Soars 5.01% Intraday on Ebola Vaccine Trial Launch, Earnings Anticipation

Stock Track

07/31

Shares of Moderna, Inc. (MRNA) soared 5.01% during intraday trading on Thursday, driven by the company's announcement of a new clinical trial for an Ebola vaccine and optimism ahead of its upcoming earnings report.

The biotech firm disclosed the launch of a Phase 1 study for its mRNA-1469 vaccine candidate, which aims to prevent Ebola virus infection. This move to expand its mRNA pipeline beyond respiratory diseases signals potential new revenue streams and reinforces Moderna's platform versatility, boosting investor confidence.

Additionally, traders are positioning ahead of Moderna's earnings release scheduled for Friday, with some market sentiment leaning toward a positive surprise, adding further upward momentum to the stock.

免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。

热议股票

{"basename":"/hans","ssrTDKData":{"titleTemplate":"%s - 老虎证券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎证券,老虎证券开户,老虎券商,老虎证券官网,老虎证券app,tigertrade老虎证券,股票,炒股,新加坡股票交易平台,投资,投资理财","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://www.itiger.com/hans/news/1199189721"},"companyName":"老虎证券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"1199189721\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/1199189721?lang=zh_CN&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-07-31 02:51","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1199189721","market":"nz","top_or_hot":-1,"title":"Stock Track | Moderna Soars 5.01% Intraday on Ebola Vaccine Trial Launch, Earnings Anticipation","media":"Stock Track","content":"<p>Shares of Moderna, Inc. (MRNA) soared 5.01% during intraday trading on Thursday, driven by the company's announcement of a new clinical trial for an Ebola vaccine and optimism ahead of its upcoming earnings report.</p><p>The biotech firm disclosed the launch of a Phase 1 study for its mRNA-1469 vaccine candidate, which aims to prevent Ebola virus infection. This move to expand its mRNA pipeline beyond respiratory diseases signals potential new revenue streams and reinforces Moderna's platform versatility, boosting investor confidence.</p><p>Additionally, traders are positioning ahead of Moderna's earnings release scheduled for Friday, with some market sentiment leaning toward a positive surprise, adding further upward momentum to the stock.</p>","source":"ai_movement_en","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Stock Track | Moderna Soars 5.01% Intraday on Ebola Vaccine Trial Launch, Earnings Anticipation</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nStock Track | Moderna Soars 5.01% Intraday on Ebola Vaccine Trial Launch, Earnings Anticipation\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1086803395\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Stock Track </p>\n<p class=\"h-time\">2026-07-31 02:51</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>Shares of Moderna, Inc. (MRNA) soared 5.01% during intraday trading on Thursday, driven by the company's announcement of a new clinical trial for an Ebola vaccine and optimism ahead of its upcoming earnings report.</p><p>The biotech firm disclosed the launch of a Phase 1 study for its mRNA-1469 vaccine candidate, which aims to prevent Ebola virus infection. This move to expand its mRNA pipeline beyond respiratory diseases signals potential new revenue streams and reinforces Moderna's platform versatility, boosting investor confidence.</p><p>Additionally, traders are positioning ahead of Moderna's earnings release scheduled for Friday, with some market sentiment leaning toward a positive surprise, adding further upward momentum to the stock.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"MRNA","symbol_name":"Moderna, Inc.","start_time":0,"source_url":"","article_id":"1199189721","we_media_id":"1086803395","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1199189721","pubTimestamp":1785437464,"columns":[],"sourceInfo":{"source_id":"ai_movement_en","name":"Stock Track"},"weMediaInfo":{"media_name":"Stock Track","introduction":"Track stock‘s movements and relevant news","home_visible":1,"id":"1086803395","head_image":"https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390"},"summary":"Shares of Moderna, Inc. (MRNA) soared 5.01% during intraday trading on Thursday, driven by the company's announcement of a new clinical trial for an Ebola vaccine and optimism ahead of its upcoming...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"MRNA":"Moderna, Inc."},"translate_title":"股票跟踪 | 埃博拉疫苗试验启动，Moderna 盘中飙升 5.01%，盈利预期","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"MRNA":1},"content_text":"Shares of Moderna, Inc. (MRNA) soared 5.01% during intraday trading on Thursday, driven by the company's announcement of a new clinical trial for an Ebola vaccine and optimism ahead of its upcoming earnings report.The biotech firm disclosed the launch of a Phase 1 study for its mRNA-1469 vaccine candidate, which aims to prevent Ebola virus infection. This move to expand its mRNA pipeline beyond respiratory diseases signals potential new revenue streams and reinforces Moderna's platform versatility, boosting investor confidence.Additionally, traders are positioning ahead of Moderna's earnings release scheduled for Friday, with some market sentiment leaning toward a positive surprise, adding further upward momentum to the stock.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":true,"editions":null,"column":"","sentiment":"2","news_tag":"movement","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":1,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"}}}